iRadimed (NASDAQ:IRMD) CEO Roger Susi Sells 2,500 Shares of Stock

iRadimed Corporation (NASDAQ:IRMD) CEO Roger Susi sold 2,500 shares of iRadimed stock in a transaction dated Tuesday, April 7th. The shares were sold at an average price of $94.84, for a total value of $237,100.00. Following the completion of the sale, the chief executive officer directly owned 2,217,500 shares in the company, valued at $210,307,700. This represents a 0.11% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

iRadimed Price Performance

IRMD opened at $93.49 on Wednesday. The business’s 50-day moving average price is $99.50 and its two-hundred day moving average price is $91.90. iRadimed Corporation has a 1 year low of $47.48 and a 1 year high of $107.90. The company has a market capitalization of $1.20 billion, a price-to-earnings ratio of 53.42 and a beta of 1.11.

iRadimed (NASDAQ:IRMD) last released its earnings results on Tuesday, February 10th. The medical equipment provider reported $0.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.49 by $0.05. The business had revenue of $22.69 million for the quarter, compared to the consensus estimate of $21.60 million. iRadimed had a return on equity of 23.83% and a net margin of 26.82%.iRadimed has set its Q1 2026 guidance at 0.440-0.480 EPS and its FY 2026 guidance at 2.060-2.210 EPS. Sell-side analysts anticipate that iRadimed Corporation will post 1.66 earnings per share for the current fiscal year.

iRadimed Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, March 6th. Investors of record on Monday, February 23rd were given a $0.20 dividend. This is an increase from iRadimed’s previous quarterly dividend of $0.17. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date of this dividend was Monday, February 23rd. iRadimed’s dividend payout ratio (DPR) is presently 45.71%.

Analyst Upgrades and Downgrades

IRMD has been the topic of a number of recent research reports. Lake Street Capital reaffirmed a “buy” rating and issued a $120.00 target price on shares of iRadimed in a research report on Wednesday, February 11th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of iRadimed in a research report on Monday, December 29th. Roth Mkm reaffirmed a “buy” rating and issued a $120.00 target price on shares of iRadimed in a research report on Tuesday, February 10th. Finally, Freedom Capital raised iRadimed to a “strong-buy” rating in a research report on Thursday, April 2nd. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $120.00.

Hedge Funds Weigh In On iRadimed

A number of institutional investors have recently bought and sold shares of IRMD. CWM LLC increased its position in iRadimed by 62.2% during the third quarter. CWM LLC now owns 550 shares of the medical equipment provider’s stock worth $39,000 after buying an additional 211 shares during the last quarter. Quarry LP acquired a new position in iRadimed during the third quarter worth approximately $40,000. Farther Finance Advisors LLC increased its position in iRadimed by 827.1% during the fourth quarter. Farther Finance Advisors LLC now owns 445 shares of the medical equipment provider’s stock worth $43,000 after buying an additional 397 shares during the last quarter. Tower Research Capital LLC TRC increased its position in iRadimed by 191.1% during the second quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock worth $45,000 after buying an additional 495 shares during the last quarter. Finally, State of Alaska Department of Revenue acquired a new position in iRadimed during the third quarter worth approximately $47,000. Institutional investors and hedge funds own 92.34% of the company’s stock.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.